Gujarat Themis Biosyn Limited manufactures pharmaceutical intermediates and active pharmaceutical ingredients, with a focus on specialized healthcare products. Its manufacturing capabilities provide exposure to India's growing pharmaceutical and API ecosystem. Increasing domestic manufacturing and global supply-chain diversification create long-term opportunities. Capacity expansion and product development can support growth. API prices, regulatory compliance, customer concentration, raw-material costs, and export demand remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹3,908 cr | — | — | 83.2 | 4.47 | 13.58 | 17.4% | 17.9% | 0.56 | ₹-124 cr | 54.2 | 1.56 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Mar 2026 | 44 | — | — | — | +17.2% | — |
| Dec 2025 | 43 | 12 | 1.14 | — | — | 28.7% |
| Sep 2025 | 78 | 23 | 1.31 | — | — | 29.8% |
| Jun 2025 | 36 | 9 | 0.83 | — | — | 25.3% |
| Mar 2025 | 38 | 12 | 1.10 | — | — | 31.8% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | — Not assessable |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✗ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✗ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 226.90 ✓ Within 25% of the 52-week high · high 469.90 ✗ RS percentile 70 or more · RS 44 Trend template - the gate, measured: a modest 21-day edge. | 4/8 | 4 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 1 - basing | |
| CAN SLIM | — C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 469.90 ✗ S more volume on up days than down days (50 sessions) · 0.90x ✗ L RS percentile 80 or more · RS 44 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 1/4 | Weak |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 470.05 ✗ Close above the prior 20-session high · 440.00 ✗ Close below the prior 20-session low · 351.00 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 1.8% — Return on capital (ROCE) · 17.9% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 24/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 51.54 ✗ P/E 15 or less · P/E 80.2 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 13.58 ✗ Current ratio 2 or more · 1.12 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 14/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✗ Current ratio rising · 1.12 ✓ No new shares issued — Margin rising (net margin) — Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 4/7 | Average |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUJTHEM this stock | -16.1 | -1.5 | +7.7 | -16.9 | — | — | 83.2 | 13.58 | 17.4 | 17.9 | — | 0.56 | 54.2 | 3,908 | — | — | 4.5 | 1.56 |
| BHAGERIA | +4.9 | +66.0 | +118.9 | +103.3 | +119.5 | +20.6 | 22.2 | 2.57 | 8.0 | 10.1 | — | 0.17 | 17.2 | 1,533 | 1,003 | 68 | 15.8 | 0.95 |
| INDOBORAX | -3.0 | -4.8 | +80.2 | +97.5 | +185.7 | — | 22.1 | 3.80 | 15.1 | 18.4 | — | 0.00 | 21.5 | 1,470 | 286 | 66 | 20.7 | 0.44 |
| ANTELOPUS | -9.2 | +16.4 | +63.8 | +92.3 | — | — | 26.6 | 5.38 | 15.9 | 21.4 | — | 0.00 | 21.0 | 3,525 | 359 | 133 | 37.8 | -0.32 |
| NGLFINE | +0.2 | -7.9 | +20.6 | +82.7 | +48.7 | — | 29.9 | 5.20 | 15.7 | 17.1 | — | 0.33 | 20.9 | 1,713 | 536 | 57 | 92.6 | 1.28 |
| RAIN | +8.3 | +5.7 | +68.3 | +77.6 | +37.5 | -7.8 | 14.0 | 0.94 | 0.6 | 8.2 | — | 1.35 | 5.8 | 7,537 | 18,464 | 667 | 16.0 | 1.42 |
| APCOTEXIND | -6.3 | +2.7 | +44.8 | +56.5 | +9.9 | +39.2 | 18.2 | 4.73 | 17.3 | 20.1 | — | 0.15 | 16.1 | 2,939 | 1,591 | 161 | 31.1 | 0.94 |
| OCCLLTD | +23.5 | +40.2 | +93.8 | +53.5 | — | — | 12.7 | 2.20 | 11.5 | 12.5 | — | 0.20 | 11.8 | 950 | 602 | 75 | 15.0 | 1.08 |
| IGPL | +2.3 | +31.2 | +32.9 | +35.8 | +8.7 | -32.7 | 21.2 | 1.30 | 0.2 | 3.1 | — | 0.27 | 17.4 | 1,733 | 2,073 | 82 | 26.5 | 1.13 |
| KINGFA | +9.9 | +26.8 | +34.5 | +35.4 | +162.1 | +542.2 | 32.7 | 6.20 | 17.4 | 23.4 | — | 0.00 | 30.9 | 8,680 | 2,684 | 266 | 195.9 | 0.52 |
| VISHNU | -14.8 | -3.8 | +7.9 | +31.1 | +80.0 | +339.6 | 27.6 | 3.88 | 14.3 | 16.3 | — | 0.49 | 17.6 | 4,144 | 1,696 | 150 | 22.3 | 0.71 |